Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clonidine
Drug ID BADD_D00502
Description Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors.[A180559] This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974.[L7237]
Indications and Usage May be used as an adjunct in the treatment of hypertension, as an epidural infusion as an adjunct treatment in the management of severe cancer pain that is not relieved by opiate analgesics alone, for differential diagnosis of pheochromocytoma in hypertensive patients, prophylaxis of vascular migraine headaches, treatment of severe dysmenorrhea, management of vasomotor symptoms associated with menopause, rapid detoxification in the management of opiate withdrawal, treatment of alcohol withdrawal used in conjunction with benzodiazepines, management of nicotine dependence, topical use to reduce intraocular pressure in the treatment of open-angle and secondary glaucoma and hemorrhagic glaucoma associated with hypertension, and in the treatment of attention-deficit hyperactivity disorder (ADHD).
Marketing Status Prescription; Discontinued
ATC Code C02AC01; N02CX02; S01EA04
DrugBank ID DB00575
KEGG ID D00281
MeSH ID D003000
PubChem ID 2803
TTD Drug ID D03SKR
NDC Product Code 69988-0033; 0597-0033; 51862-453; 50742-247; 51862-455; 0591-3508; 0591-3509; 0597-0032; 0378-0872; 0597-0031; 82089-102; 0378-0873; 0378-0871; 51862-454; 82089-103; 46708-830; 82089-101; 71511-503; 39822-2010; 39822-2000; 0591-3510; 69238-1426
Synonyms Clonidine | Klofenil | Clofenil | Chlophazolin | Clonidine Dihydrochloride | Dihydrochloride, Clonidine | Clonidine Hydrochloride | Hydrochloride, Clonidine | Clonidine Monohydrochloride | Monohydrochloride, Clonidine | Clonidine Monohydrobromide | Monohydrobromide, Clonidine | ST-155 | ST 155 | ST155 | Gemiton | Hemiton | Isoglaucon | Klofelin | Clofelin | Clopheline | M-5041T | M 5041T | M5041T | Catapres | Catapresan | Catapressan | Dixarit
Chemical Information
Molecular Formula C9H9Cl2N3
CAS Registry Number 4205-90-7
SMILES C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionG protein-activated inward rectifier potassium channel 1P48549T380129504382; 15530503; 8872359; 7887943; 10780978; 7746270; 9346897; 10945855
Adverse drug reactionDelta-type opioid receptorP41143T589929504382; 15530503; 8872359; 7887943; 10780978; 7746270; 9346897; 10945855
Adverse drug reactionG protein-activated inward rectifier potassium channel 1P48549T3801210780978; 12684268; 9504382; 15150531
Adverse drug reactionKappa-type opioid receptorP41145T606939504382; 15530503; 8872359; 7887943; 10780978; 7746270; 9346897; 10945855
AgranulocytosisMyeloperoxidaseP05164T234718531118; 9614200; 9212779; 10681368; 9660850; 12399162; 10859143
Drug level changedCytochrome P450 3A4P08684T3784811903482; 9435993; 8941495; 11952767
Drug level increasedCytochrome P450 2D6P10635T5739210772431; 15748098; 10983742
Drug level increasedCytochrome P450 1A2P05177Not Available11503857; 9167831; 9169967; 7576262; 1511528; 8280403; 16093198; 16306002; 12480120
Seizures (incl subtypes)G protein-activated inward rectifier potassium channel 1P48549T3801210780978; 12684268; 9504382; 15150531
Seizures (incl subtypes)G protein-activated inward rectifier potassium channel 1P48549T380129504382; 15530503; 8872359; 7887943; 10780978; 7746270; 9346897; 10945855
Sinus tachycardiaG protein-activated inward rectifier potassium channel 1P48549T3801210780978; 12684268; 9504382; 15150531
Sinus tachycardiaG protein-activated inward rectifier potassium channel 1P48549T380129504382; 15530503; 8872359; 7887943; 10780978; 7746270; 9346897; 10945855
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Accommodation disorder06.02.04.001--Not Available
Affective disorder19.04.04.0010.000206%Not Available
Aggression19.05.01.0010.000514%Not Available
Agitation17.02.05.012; 19.06.02.0010.000206%
Alcohol intolerance14.02.01.001--
Alopecia23.02.02.001--
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Apnoea22.02.01.0010.000308%
Application site erythema12.07.01.001; 08.02.01.001; 23.03.06.005--Not Available
Application site pain12.07.01.004; 08.02.01.004--Not Available
Application site rash23.03.13.008; 12.07.01.016; 08.02.01.016--Not Available
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Atrioventricular block02.03.01.002--Not Available
Atrioventricular block complete02.03.01.003--
Atrioventricular block first degree02.03.01.0040.000206%
Attention deficit/hyperactivity disorder19.21.04.0010.000206%Not Available
Autonomic nervous system imbalance24.06.01.005; 17.05.01.011; 08.01.01.0100.000054%Not Available
Back pain15.03.04.0050.000308%
Blood creatine phosphokinase increased13.04.01.001--
Blood glucose increased13.02.02.002--Not Available
Blood pressure increased13.14.03.0050.000822%Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.0020.001541%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 8 Pages